REGISTER
Lilly Tirzepatide Wins 5th Indication in China
Eli Lilly’s dual GLP-1R/GIPR agonist tirzepatide has been approved in China for monotherapy in adults with type 2 diabetes, with the updated label also covering broader T2DM treatment settings. The approval marks its fifth indication in China and further strengthens its leading position in metabolic disease.

On February 12, Eli Lilly and Company announced that its dual GLP-1R/GIPR agonist tirzepatide had been approved in China for a new indication, as monotherapy for adults with type 2 diabetes mellitus (T2DM). At the same time, the updated prescribing information will cover both monotherapy and use with other glucose-lowering drugs in various T2DM treatment settings, that is, to improve glycemic control in adults with type 2 diabetes on the basis of diet and exercise.

Tirzepatide (Tirzepatide, Mufengda®) is a blockbuster drug in the metabolic field. Since its first approval in 2022, its sales momentum has been unstoppable. It entered the global top 100 drugs by sales in the year after launch and climbed into the top five in 2024, achieving global sales of USD 16.466 billion.

In 2025, the diabetes brand Mounjaro contributed USD 22.965 billion, up 99%, while the weight-loss brand Zepbound recorded USD 13.542 billion with 175% growth, bringing combined revenue to USD 36.507 billion. This means tirzepatide surpassed Novo Nordisk’s semaglutide and Merck’s Keytruda to become the top-selling drug of 2025.

To date, tirzepatide has been approved in the four major mainstream markets of China, the United States, Japan, and Europe, with indications expanded from type 2 diabetes to obesity and obstructive sleep apnea (OSA). Indications under investigation also include heart failure, cardiovascular risk, MASH, chronic kidney disease, and other conditions, gradually covering the spectrum of metabolism-related diseases.

SURPASS-CN-MONO (registration numbers NCT05963022/CTR20232036) is a randomized, double-blind, placebo-controlled study designed to explore the efficacy and safety of tirzepatide 5 mg, 10 mg, or 15 mg as monotherapy versus placebo in Chinese adults with type 2 diabetes whose disease was inadequately controlled with diet and exercise.

The study enrolled 206 patients, with the primary endpoint being change in HbA1c from baseline at Week 40.

The results showed that after 40 weeks of treatment, HbA1c decreased by 2.19%, 1.75%, and 2.03% from baseline in the tirzepatide 5 mg, 10 mg, and 15 mg monotherapy groups, respectively, whereas the placebo group showed only a 0.77% decrease.

At Week 40, the proportions of patients achieving glycemic control, defined as HbA1c below 7.0%, were 90.38%, 86.36%, and 83.33% in the three treatment groups, respectively, compared with only 38.30% in the placebo group.

With this latest approval, tirzepatide now has five approved indications in China. According to the Insight database, previously approved indications include the following:

  • Improvement of glycemic control in adults with type 2 diabetes on the basis of diet and exercise when blood glucose remains inadequately controlled despite treatment with metformin and/or sulfonylureas;
  • Long-term weight management in adults whose BMI meets one of the following criteria on the basis of diet control and increased exercise: at least 28 kg/m² for obesity, or at least 24 kg/m² for overweight with at least one weight-related comorbidity;
  • Treatment of moderate to severe obstructive sleep apnea in adults with obesity, with use of this indication to be combined with diet control and increased exercise;
  • Improvement of glycemic control in adults with type 2 diabetes on the basis of diet and exercise in combination with insulin, with or without oral glucose-lowering drugs.

As the first pharmaceutical company in history to reach a market capitalization of more than USD 1 trillion, Eli Lilly and Company mainly focuses on four major disease areas: metabolism, including glucose lowering and weight loss, oncology, immunology, and neuroscience. The metabolic business is Lilly’s core segment, and its next-generation obesity pipeline will support performance in the post-tirzepatide era.

At present, Lilly has also positioned the oral GLP-1R agonist orforglipron and the GLP-1R/GCGR/GIPR triple agonist retatrutide in the GLP-1 arena.

According to the Insight database, orforglipron has already taken the lead in launching regulatory submissions in major global markets and is close to commercialization. In December 2025, the U.S. Food and Drug Administration accepted its NDA, and in January 2026, its marketing application was also accepted by China’s Center for Drug Evaluation.

With ongoing indication expansion for established advantaged pipelines and continued progress of later-stage pipelines, patients with chronic diseases may see a new chapter of therapeutic innovation in the future. For pharmaceutical companies participating in this field, profound opportunities and intense competition coexist.

0
0
Loading